Cargando…
Inadvertent Transfer of Murine VL30 Retrotransposons to CAR-T Cells
For more than a decade, genetically engineered autologous T-cells have been successfully employed as immunotherapy drugs for patients with incurable blood cancers. The active components in some of these game-changing medicines are autologous T-cells that express viral vector-delivered chimeric antig...
Autores principales: | Lee, Sung Hyun, Hao, Yajing, Gui, Tong, Dotti, Gianpietro, Savoldo, Barbara, Zou, Fei, Kafri, Tal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450689/ https://www.ncbi.nlm.nih.gov/pubmed/36081760 http://dx.doi.org/10.1155/2022/6435077 |
Ejemplares similares
-
Genomic analysis of mouse VL30 retrotransposons
por: Markopoulos, Georgios, et al.
Publicado: (2016) -
Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021) -
Challenges of driving CD30-directed CAR-T cells to the clinic
por: Grover, Natalie S., et al.
Publicado: (2019) -
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
por: Tschernia, Nicholas P, et al.
Publicado: (2023) -
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes
por: Caruana, Ignazio, et al.
Publicado: (2015)